QC
ABOS icon

Quadrature Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Quadrature Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,046
Closed -$103K – 1315
2025
Q4 		$103K Buy
+49,046
New +$97.3K ﹤0.01% 1097

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Quadrature Capital's ABOS Position: Q1 2026 in Review

Quadrature Capital sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 49,046 shares — an estimated $103K sold.

Quadrature Capital first reported a position in ABOS in Q4 2025 and held it in 1 quarter. The position peaked at $103K in Q4 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Quadrature Capital reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 49,046 Acumen Pharmaceuticals shares in Q1 2026, an estimated $103K.
  • Quadrature Capital first reported a position in Acumen Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Acumen Pharmaceuticals position peaked at $103K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.